We previously reported on Amgen’s complaint in the Central District of California seeking a declaratory judgment that 27 Genentech patents are not infringed by Genentech’s bevacizumab biosimilar (Mvasi®). On November 15, 2017, Genentech moved to dismiss the Amgen DJ action. Genentech argues that the court lacks jurisdiction over Amgen’s DJ action…